Bone effects of anastrozole in japanese postmenopausal patients with breast cancer? results of one year follow up by multicenter prospective study, (sbccsg 06:umin 514)

Bone Effects of Anastrozole in Japanese
Postmenopausal Breast Cancer Patients:
Results of a Two Year Follow-up by Multicenter Prospective Study (SBCCSG-06)
Saitama Breast Cancer Clinical Study Group
Hideki Takeuchi, Kazushige Futsuhara, Takashi Yoshida, Hiroyuki Takei, Makoto Kojima, Shigeto Ueda, Tsuyoshi Saito, Satoko Nakano, Sumio Yamashita, Toru Kuroda, Satoshi Hata, Kenichi Inoue, Hiroshi Miyake, Yasuhiko Hakamada, Masafumi Kurosumi, Toshihiro Kai, Toshio Tabei Background
Anastrozole is superior to tamoxifen in terms of efficacy • Overall fracture rate was 1.8% (6/330) during the Figure 1. Trial profile
and safety for adjuvant treatment in postmenopausal median follow-up period of 33.0 months [Table 3, 4].
patients with hormone-responsive early breast cancer. • BMD was decreased significantly in any method of Based on therapeutic guidelines, anastrozole is widely 330 eligible analysed for primary endpoint (ITT) used for adjuvant treatment in Japan. However, there • The changes in BMI and weight were not significant.
are only a few reports on the safety of anastrozole in • In the subset analyses, in only the DXA and 65> Japanese patients, especially the long-term effects on group, the height was decreased significantly despite the fact that the change in BMD was not • Anastrozole treatment was well tolerated, that was Objective
indicated by 5.5% of lower occurrence rate for The aim of this study is to evaluate the frequency of 259 continued(includes 4 fracture continued ANZ) bone fracture and impact on BMD during the course of Table 1. Patients profile
Table 2. Baseline characteristics
adjuvant treatment with anastrozole in Japanese patients. This is a report on the updated two year No. of patients (%)
follow-up data after the first year of analysis.
Tumor stage
Materials and Methods
Hormone receptor
• From December 2005 to November 2007, 350 operable breast cancer patients were enrolled in this clinical trial from 12 centers in Saitama, Table 3. The BMD (YAM) and details of fracture cases
Inclusion criteria
• Operable breast cancer, proven ER and/or PgR • Completed primary surgery: partial resection or modified radical mastectomy and sentinel lymphnode biopsy or axillary dissection, and chemotherapy • Postmenopausal women: intact uterus and Table 4. Comparisons between ATAC trial and SBCCSG-06
postmenopausal range of serum FSH and E2 level; Exclusion criteria
• Severe concomitant disease: hepatic dysfunction; * ATAC Trialists’ Group. Lancet. 2002; 359: 2131-39.
Table 5. Changes in BMD between measuring Table 6. Changes in Height between measuring
methods and age (<65, 65)
methods and age (<65, 65)
The eligible patients received adjuvant anastrozoletreatment (1mg/day) for up to 5 years. During the course of treatment, they were scheduled to undergo clinical examination for bone fracture and annual check of BMD (YAM: young-adult-mean). The oral bisphosphonate could be used concomitantly with anastrozole for patients diagnosed with osteoporosis (YAM < 70%). Trial protocol was stopped if any bone fracture was occurred, the patient refused to continue, recurrence and secondary cancer were confirmed, or on the recommendation of the investigator. The data were mainly analysed for changes in parameters with Table 7. Adverse events
repeated ANOVA and two-sided p values were used. Measuring method of BMD
• DXA : dual-energy X-ray absorptiometry for • MD:microdensitometry for metacarpal bone Primary endpoint
Secondary endpoints
• Bone fracture rate on concomitant oral Conclusions
In this multicenter prospective study, the fracture rate on anastrozole treatment in Japanese patients was lower than that of Western population despite the fact that there was a significant reduction of BMD after 2 years of treatment with anastrozole. Annual monitoring of BMD is mandatory in treated patients. Moreover, further long-term follow-up data is necessary to elucidate the racial disparities of the safety profile of anastrozole.


Microsoft word - webdesk-rapport de spam.doc

Utilisation du nouveau système Anti Spam Principe de L’Anti Spam. 3 Les scores . 4 Utilisation du rapport de Spam . 5 Liste noire et liste blanche . 7 Consultation des dossiers Spams et Quarantaine . 8 Contact . 9 Introduction L'objectif de ce document est d'aider à comprendre le système de gestion du rapport anti Spam que vous recevez tout les matins. Qu’est ce qu

Summary of findings 6-21-12

Summary of Hall, et al. study “Mid-Century Warming in the Los Angeles Region.” Prepared by Paul Bunje PhD The first results from the “Climate Change in the Los Angeles Region” project, sponsored by the City of Los Angeles and US Department of Energy covers temperature changes. Future results will cover other elements of climate change (precipitation, snowpack, winds, clouds, etc.). T

Copyright © 2014 Medical Pdf Articles